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Recent studies have revealed that PDGF plays a role in promoting progressive tumor growth in several cancers, in-
cluding gastric cancer. Cancer-associated fibroblasts, pericytes, and lymphatic endothelial cells in stroma express
high levels of PDGF receptor (PDGF-R); cancer cells and vascular endothelial cells do not. Mammalian target of ra-
pamycin (mTOR) is a serine/threonine kinase that increases the production of proteins that stimulate key cellular
processes such as cell growth and proliferation, cell metabolism, and angiogenesis. In the present study, we exam-
ined the effects of PDGF-R tyrosine kinase inhibitor (nilotinib) andmTOR inhibitor (everolimus) on tumor stroma in an
orthotopic nude mice model of human gastric cancer. Expression of PDGF-B and PDGF-RβmRNAs was associated
with stromal volume. Treatment with nilotinib did not suppress tumor growth but significantly decreased stromal
reactivity, lymphatic invasion, lymphatic vessel area, and pericyte coverage of tumormicrovessels. In contrast, treatment
with everolimusdecreased tumor growth andmicrovessel density but not stromal reactivity. Nilotinib andeverolimus in
combination reduced both the growth rate and stromal reaction. Target molecule-based inhibition of cancer-stromal
cell interaction appears promising as an effective antitumor therapy.
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In 2011, gastric cancer was reported as the world’s fourth most com-
mon cancer in men and fifth most common in women [1]. The major
cause of gastric cancer-associatedmortality is metastasis. Recent studies
in molecular and cellular biology have shown that tumor growth and
metastasis are not determined by cancer cells alone but also by various
stromal cells. The stroma constitutes a large part of most solid tumors,
and the cancer-stromal cell interaction contributes functionally to
tumor growth and metastasis [2,3]. Tumor stroma contains many dif-
ferent types of cells, including activated fibroblasts (myofibroblasts),
endothelial cells, pericytes, and inflammatory cells. It has become clear
that activated fibroblasts in cancer stroma are key modulators of tumor
progression. As such, they are called cancer-associated fibroblasts
(CAFs) [4]. Although the mechanisms that regulate activation of fibro-
blasts and their accumulation in tumors are not fully understood,
PDGF, transforming growth factor β, and fibroblast growth factor 2
are known to be partly involved in this process [5].PDGF and PDGF receptor (PDGF-R) are expressed in many
human neoplasms, including prostate [6], lung [7], colon [8], and
breast [9,10] neoplasms. We previously reported expression of
PDGF-R in CAFs [11], pericytes, and lymphatic endothelial cells
in the stroma of gastric cancer [12] but not in cancer cells or vascular
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of tumor cells in an autocrinemanner [13] and to stimulate angiogenesis
[14], recruit pericytes [13,15], and control interstitial fluid pressure in
stroma, influencing transvascular transport of chemotherapeutic agents
in a paracrine manner [16]. Imatinib mesylate is a protein-tyrosine
kinase inhibitor that was developed initially for its selectivity against
breakpoint cluster region-Abelson (BCR-ABL) fusion protein
[17]. The following additional tyrosine kinases are inhibited by
imatinib: c-KIT, the receptor for KIT ligand (stem cell factor), two
structurally similar PDGF-Rs (PDGF-Rα and PDGF-Rβ), and dis-
coidin domain receptors (DDR1 and DDR2) [18,19]. Nilotinib has
been established as a drug with potency superior to that of imatinib as
an inhibitor of BCR-ABL. Nilotinib also inhibits the tyrosine kinase
activity of the PDGF and c-KIT receptors DDR1 and DDR2 with
efficacy similar that of imatinib [20,21].
The mammalian target of rapamycin (mTOR), a serine/threonine
kinase, integrates multiple signaling pathways, including those
that control growth and survival of tumor cells and angiogenesis.
Mutations in upstream regulators of the mTOR signaling pathway,
including epithelial growth factor receptor [22], phosphatidylinositol-3
kinase (PI3K) [22], and phosphatase and tensin homolog (PTEN)
[23], have been frequently observed in human gastric cancer tissues.
Phosphorylated mTOR, indicative of mTOR activation [24], has
been positively correlated with tumor progression and poor survival
in patients with gastric cancer [24,25]. mTOR exists in two com-
plexes, mTORC1 and mTORC2 [26]. mTORC1 activation con-
trols cell growth by regulating translation, ribosome biogenesis,
autophagy, and metabolism [27]. mTORC2 phosphorylates Akt,
serum/glucocorticoid regulated kinase 1 (SGK1), and protein kinase
C to control multiple functions including cell survival and cyto-
skeletal organization [28]. mTOR also increases the translation of
hypoxia-inducible factor 1α, which drives the expression of angio-
genic growth factors such as vascular endothelial growth factor
(VEGF), resulting in new vasculature. Everolimus is one of the rapalogs
that inhibit mTORC1-mediated phosphorylation of S6 kinase 1
(S6K1) and 4E-binding protein 1 (4E-BP1), leading to decreased cell
migration and invasion [29].
We examined, in an orthotopic nude mice model, whether nilotinib
and everolimus have a synergic inhibitory effect on growth and
metastasis of gastric cancer. We focused on cancer-stromal cell inter-
actions because both the molecules and the cells targeted by these two
drugs differ.Materials and Methods
Human Gastric Cancer Cell Lines and Culture Conditions
Three gastric cancer cell lines, including high PDGF-B–expressing
cells (TMK-1 and MKN-1) and low PDGF-B–expressing cells
(KKLS), were used in this study [12]. The TMK-1 cell line (poorly
differentiated adenocarcinoma) was kindly provided by Dr E. Tahara
(Hiroshima University, Hiroshima, Japan). The MKN-1 cell line
(adenosquamous carcinoma) was obtained from the Health Science
Research Resources Bank (Osaka, Japan), and the KKLS cell line
(undifferentiated carcinoma) was kindly provided by Dr Y. Takahashi
(International University of Health and Welfare, Chiba, Japan). These
cell lines were maintained in Dulbecco’s Modified Eagle’s Medium
with 10% FBS (Sigma-Aldrich, St Louis, MO) and a penicillin-
streptomycin mixture.Animals and Orthotopic Implantation of Tumor Cells
Female athymic nude BALB/c mice were obtained from Charles
River Japan (Tokyo, Japan). The mice were maintained under specific
pathogen-free conditions and used at 5 weeks of age. The study was
carried out after permission was granted by the Committee on Animal
Experimentation of Hiroshima University. TMK-1, MKN-1, and
KKLS cells were harvested from subconfluent cultures by brief
exposure to 0.25% trypsin and 0.02% EDTA. Trypsinization was
stopped with medium containing 10% FBS, and the cells were washed
once in serum-free medium and resuspended in Hank’s balanced salt
solution. Only suspensions consisting of single cells with >90% via-
bility were used. To produce gastric tumors, 1 × 106 cells in 50 μl of
Hank’s balanced salt solution were injected into the gastric wall of
nude mice under observation with a zoom stereomicroscope (Carl
Zeiss, Gottingen, Germany).Treatment of Established Human Gastric Cancer Tumors
Growing in the Gastric Wall of Nude Mice
To compare the therapeutic effects of imatinib and nilotinib on
stromal cells, we performed preliminary experiments. The optimal
biologic dose was used, as determined previously [30–32]. Seven
days after the orthotopic implantation of TMK-1 or MKN-1 tumor
cells, mice were randomized into the following three groups: those
given water daily by oral gavage (control group), those given 50 mg/kg
per day imatinib by oral gavage, and those given 50 mg/kg per
day nilotinib by oral gavage. Treatments continued for 21 days,
and the mice were killed on day 22. Excised tumors were subjected
to immunohistochemistry.
To compare and evaluate the effect of combination therapy, 14 days
after orthotopic implantation of TMK-1 tumor cells, mice were ran-
domized to one of the following four treatments (n = 6 in each group):
1) daily oral gavage of water (control group), 2) daily oral gavage of
nilotinib (100 mg/kg; nilotinib group), 3) daily oral gavage of everoli-
mus (2 mg/kg; everolimus group), and 4) daily oral gavage of nilotinib
(100 mg/kg) and everolimus (2 mg/kg; combination group). Combi-
nation studies with imatinib and everolimus were not performed due
to drug-drug interactions that effect the pharmacokinetic profiles and
tolerability of the agents in vivo. The mice were treated for 35 days,
and then killed and subjected to necropsy.Necropsy Procedures and Histologic Studies
Mice bearing orthotopic tumors were killed by diethyl ether. Body
weights were recorded. After necropsy, tumors were excised andweighed.
For immunohistochemistry, one part of the tumor tissue was fixed in
formalin-free IHC Zinc Fixative (BD Pharmingen, San Diego, CA)
and embedded in paraffin, and the other part was embedded in OCT
Compound (Miles Laboratories, Elkhart, IN), rapidly frozen in liquid
nitrogen, and stored at −80°C. All macroscopically enlarged regional
(celiac and para-aortal) lymph nodes were harvested, and the presence
of metastatic disease was confirmed by histologic examination.Patients and Tumor Specimens
To examine the clinical importance of PDGF/receptor signaling
and mTOR signaling, endoscopic biopsy or surgical specimens were
obtained from 29 patients with gastric cancer who underwent surgical
resection at Hiroshima University Hospital. The specimens were
examined by quantitative RT-PCR (RT-PCR) and immunohisto-
chemistry, respectively. The biopsy specimens were snap frozen in
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specimens was in accordance with the Ethical Guidelines for Human
Genome/Gene Research of the Japanese Government. Patient
informed consent was not required, but identifying information for
all samples was removed before analysis.
Quantitative RT-PCR Analysis
Total RNA was extracted from the gastric cancer cell lines and
biopsy specimens with an RNeasy Kit (Qiagen, Valencia, CA) accord-
ing to the manufacturer’s instructions. cDNA was synthesized from
1 μg of total RNA with a first-strand cDNA synthesis kit (Amersham
Biosciences, Piscataway, NJ). After reverse transcription of RNA into
cDNA, quantitative RT-PCR was performed with a LightCycler
FastStart DNA Master SYBR Green I kit (Roche Diagnostics, Basel,
Switzerland) according to the manufacturer’s recommended protocol.
Reactions were carried out in triplicate. To correct for differences in
both RNA quality and quantity between samples, values were normal-
ized to those of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The mRNA ratio between gastric carcinoma tissues (T) and corre-
sponding normal mucosa (N) was calculated and expressed as the
T/N ratio. Primers for PCR were designed with specific primer analysis
software (Primer Designer; Scientific and Educational Software, Cary,
NC), and specificity of the sequences was confirmed by FASTA
[European Molecular Biology Laboratory (EMBL) Database, Heidelberg,
Germany]. Respective primer sequences, annealing temperatures, and
PCR cycles were as previously reported [12].
Reagents
Imatinib (Gleevec), nilotinib (Tasigna), and everolimus (Afinitor)
were kindly provided by Novartis Pharma (Basel, Switzerland).
Imatinib and everolimus were diluted in sterile water for oral adminis-
tration. Nilotinib was disolved in 0.5% hydroxypropylmethylcellulose
aqueous solution containing 0.05% Tween 80 at the concentration
of 4 mg/ml and then diluted in sterile water. Primary antibodies
were purchased as follows: polyclonal rabbit anti–PDGF-Rβ, polyclonal
rabbit antiphosphorylated PDGF-Rβ (p–PDGF-Rβ), and polyclonal
rabbit anti-human VEGF-A (sc-152) from Santa Cruz Biotechnology
(Santa Cruz, CA); rat anti-mouse CD31 [(platelet endothelial cell
adhesion molecule (PECAM1)] from BD Pharmingen; mouse anti-
desmin monoclonal antibody from Molecular Probes (Eugene, OR);
rabbit anti–α-smooth muscle actin (α-SMA; ab5694) from Abcam
(Cambridge, United Kingdom); Ki-67–equivalent antibody (MIB-1)
from Dako (Carpinteria, CA); monoclonal rat anti-mouse lymphatic
vessel endothelial hyaluronan receptor 1 (Lyve-1) antibody from
R&D Systems (Minneapolis, MN); polyclonal rabbit anti-mouse
type I collagen from Novotec (Saint Martin La Garenne, France);
and monoclonal rabbit anti-mouse S6 ribosomal protein antibody
(No. 2217) and monoclonal rabbit antiphosphorylated mouse S6
ribosomal protein antibody (No. 4858) fromCell Signaling Technology
(Beverly, MA). The following fluorescent secondary antibodies were
used: Alexa 488-conjugated goat anti-rabbit IgG, Alexa 488-conjugated
goat anti-rat IgG, and Alexa 546-conjugated goat anti-rabbit IgG (all
from Molecular Probes).
Immunofluorescence for PDGF-Rβ and p–PDGF-Rβ and
Double Immunofluorescence for CD31 (Vascular Endothelial
Cells) and Desmin (Pericytes)
Fresh-frozen specimens of TMK-1 human gastric cancer tissue
obtained from nude mice were cut into 8-μm sections and mountedon positively charged slides. After fixation with ice-cold acetone
for 20 minutes, washing and blocking were performed as previously
described [11]. The slides were incubated for 3 hours at room
temperature with primary antibody against PDGF-Rβ or p–PDGF-Rβ.
Slides were incubated for 1 hour at room temperature with Alexa 546-
conjugated goat anti-rabbit IgG secondary antibody and then nuclear
counterstained with 4′,6-diamidino-2-phenylindole (DAPI) for 10 min-
utes. PDGF-Rβ or p–PDGF-Rβ was identified by red fluorescence.
For double immunofluorescence, after fixation, washing, and block-
ing, the slides were incubated overnight at 4°C with Fab fragment goat
anti-mouse IgG ( Jackson ImmunoResearch Laboratories, West
Grove, PA) to block endogenous immunoglobulins. Then, slides were
incubated with the primary antibody desmin for 3 hours at room tem-
perature. This was followed by incubation for 1 hour at room temper-
ature with Alexa 546-conjugated goat anti-mouse IgG secondary
antibody. Slides were then incubated for 3 hours at room temperature
with antibody against CD31 and incubated for 1 hour at room tem-
perature with Alexa 488-conjugated goat anti-rat IgG secondary anti-
body. The samples were then nuclear counterstained with DAPI.
Endothelial cells were identified by green fluorescence, whereas peri-
cytes were identified by red fluorescence. The coverage of pericytes
on endothelial cells was determined by counting CD31-positive cells
in direct contact with desmin-positive cells in five randomly selected
microscopic fields (at ×200 magnification) [33].
Confocal Microscopy
Confocal fluorescence images were obtained with the use of a ×20
or ×40 objective lens on a Carl Zeiss LSM laser scanning microscopy
system (Carl Zeiss Inc, Thornwood, NY).
Immunohistochemistry and Terminal Deoxynucleotide
Transferase-Mediated dUTP-Biotin Nick End Labeling
Immunohistochemistry for α-SMA, type I collagen, Ki-67, Lyve-1,
phosphorylated S6 ribosomal protein, or VEGF-A was performed
on formalin-free zinc-fixed, paraffin-embedded tissues cut into serial
4-μm sections. After deparaffinization and rehydration, tissue sections
to be stained for α-SMA, type I collagen, Ki-67, Lyve-1, phosphory-
lated S6 ribosomal protein, or VEGF-A were pretreated by microwav-
ing them twice for 5 minutes in Dako REAL Target Retrieval Solution
(Dako). Primary antibodies were applied to the slides and incubated
overnight in humidified boxes at 4°C. After incubation for 1 hour at
room temperature with corresponding peroxidase-conjugated second-
ary antibodies, a positive reaction was detected by exposure to stable
DAB for 5 to 10 minutes. Slides were counterstained with hematoxylin
for visualization of the nucleus. Apoptotic cells in tissue sections were
detected by terminal deoxynucleotide transferase-mediated deoxyuridine
triphosphates (dUTP)-biotin nick end labeling (TUNEL) assay with the
ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (Chemicon
Intl, Temecula, CA) according to the manufacturer’s instructions.
Quantification of the CAF (α-SMA–Positive), Collagen
(Type I Collagen-Positive), Microvessel (CD31-Positive),
and Lymphatic Vessel (Lyve-1–Positive) Areas
To evaluate angiogenic and lymphangiogenic activity of the tumors,
the areas of vascular and lymphatic microvessels were quantified.
Ten random fields at ×200 (for vascular microvessels) or ×100 (for
lymphatic microvessels) magnification were captured for each tumor,
and the outline of each vascular or lymphatic microvessel including
a lumen was manually traced. The areas were then calculated with
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Rasband, Bethesda, MD). The areas of CAFs and extracellular matrix
(ECM) were also determined from the respective areas of α-SMA–
positive and type I collagen-positive staining from 10 optical fields
(original magnification, ×100) of different sections.Figure 1. Expression of PDGF-B and PDGF-RβmRNAs in relation to stro
Stromal volume and ECM production were evaluated by immunostain
sified as those with low (below median value) and those with high (h
expression in cancer tissue to that of normal mucosa. The bars represe
immunohistochemistry for α-SMAand type I collagen in orthotopic xen
MKN-1 tumors) have rich stroma,whereas tumorswith lowPDGF-BmR
associated fibroblasts. Immunohistochemistry for p-S6RPs in primary ga
of cancer cells in TMK-1 orthotopic tumor and in differentiated and uDetermination of the Ki-67 Labeling Index
and the Apoptotic Index
The Ki-67 labeling index (Ki-67 LI) was determined by light
microscopy at the site of the greatest number of Ki-67–positive cells.
Cells were counted in 10 fields at ×200magnification, and the numbermal volume and ECMproduction in human gastric cancer tissues (A).
ing for α-SMA and type I collagen, respectively. Tissues were clas-
igher than median value) expression levels. T/N ratio is the ratio of
nt means+ SE. *P< .05. Hematoxylin and eosin (H&E) staining and
ografts (B). Tumorswith highPDGF-BmRNAexpression (TMK-1 and
NAexpression (KKLS tumors) have scanty stroma. CAFs are cancer-
stric cancer tissue (C). Expressionof p-S6RP is detected in cytoplasm
ndifferentiated human gastric cancers.
Figure 2. Effects of imatinib and nilotinib on stroma of TMK-1 andMKN-1 tumors. H&E staining and immunohistochemistry for α-SMA and
Lyve-1 in TMK-1 (A) and MKN-1 (B) orthotopic tumors are shown. The stromal reaction (evaluated by immunostaining for α-SMA) was sig-
nificantly reduced in mice treated with imatinib and nilotinib in comparison to that in control group mice (C and D). Lymphatic vessel area
(Lyve-1–positive area) decreased especially in the group of mice with TMK-1 tumors treated with imatinib and nilotinib (C and D). T, tumor
nest; arrows, dilated lymphatic vessels. *P < .05; bars, SE.
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expressed as a percentage. The number of apoptotic cells was counted
in 10 random 0.14-mm2 fields at ×200 magnification. The apoptotic
index was taken as the ratio of positively stained tumor cells and bodies
to all tumor cells and expressed as a percentage for each case.Statistical Analysis
Values are expressed as means ± SE. Between-group differences in
murine body weight, tumor weight, and the areas of α-SMA–positive,
type I collagen-positive, CD31-positive, and Lyve-1–positive cells
were analyzed by Wilcoxon/Kruskal-Wallis test. Differences in the
incidence of lymph node metastasis were analyzed by Fisher’s exact test.
Differences in the percentages of Ki-67–positive cells and TUNEL-
positive cells were analyzed by unpaired Student’s t test or χ2 test as
appropriate. A P value of <.05 was considered statistically significant.Results
Expression of PDGF-B and PDGF-Rβ in Relation to Stromal
Reaction in Human Gastric Cancers
We first examinedmRNA expression levels of PDGF-B and PDGF-Rβ
in relation to stromal reaction in human gastric cancer tissues. Stromal
reaction was evaluated as stromal volume and as ECM production by
immunohistochemistry for α-SMA and type I collagen, respectively
(Figure 1A). Stromal volume was significantly higher in the PDGF-B–
high group than in the PDGF-B–low group. ECM production tended
to be greater in the PDGF-B–high group. PDGF-Rβ expression was
clearly related to stromal reaction.
TMK-1 andMKN-1 cells (high PDGF-B–expressing cells) produced
orthotopic tumors with abundant stroma; however, KKLS cells (low
PDGF-B–expressing cells) did not (Figure 1B). Thus, the PDGF/
receptor system may be involved in tumor–stromal cell interaction.Table 1. Effects of Nilotinib and Everolimus on Orthotopic TMK-1 Tumors per Treatment Group.Group Body Weight (g) Tumor Incidence Tumor Weight (g) Lymph Node MetastasisControl 21.8 (17.8-24.6) 5/5 0.33 (0.07-0.72) 3/5
Nilotinib (100 mg/kg) 20.6 (18.5-23.5) 5/5 0.35 (0.10-0.45) 4/5
Everolimus (2 mg/kg) 22.0 (20.4-23.9) 4/6 0.08 (0.00-0.15)* 3/6
Nilotinib (100 mg/kg) + everolimus (2 mg/kg) 21.3 (16.3-22.1) 1/6 0.006 (0.00-0.04)† 0/6Control group (n = 5), nilotinib group (n = 5), everolimus group (n = 6), and nilotinib plus everlimus group (n = 6).
Ranges are shown in parentheses.
*P < .05 versus control group values.
†P < .01 versus control group values.
Figure 3. Effects of nilotinib and/or everolimus on TMK-1 orthotopic tumors. Phosphorylation of downstream target protein for nilotinib and
everolimus. Treatmentwith nilotinib inhibited expression of p–PDGF-Rβ. Treatmentwith everolimus inhibited phosphorylation of S6RP (A).
H&E and immunohistochemical staining for α-SMA, Lyve-1, and VEGF-A in TMK-1 orthotopic gastric tumor (B). Effects of nilotinib and ever-
olimus on microvessels in TMK-1 tumor. Pericyte coverage on tumor-associated endothelial cells in the TMK-1 gastric tumors (C). Treat-
ment with nilotinib reduced pericyte coverage of microvessels. Vascular endothelial cells were identified by green fluorescence, whereas
desmin (pericytes) were identified by red fluorescence.
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Gastric Cancers
We next examined activation of the mTOR pathway in human gas-
tric cancer tissues obtained surgically. Phosphorylation of S6 (p-S6)
ribosomal proteins (p-S6RP) was assessed to evaluate activity of the
mTOR signaling pathway. In all 29 human gastric cancers, tumor cells
were shown by immunohistochemistry to express p-S6RP. Although
expression of p-S6RP was detected in both differentiated and undiffer-
entiated gastric cancers (Figure 1C ), the staining was heterogeneous;that is, it was weak at the invasive edge (staining not shown). Tumor
cells in xenografts implanted into nude mice were also positive for
p-S6RP (Figure 1C ).Effects of Imatinib and Nilotinib on Tumor Stroma
In the first set of animal experiments, we examined the effects of
PDGF-R tyrosine kinase inhibitors, imatinib and nilotinib, on stroma
of TMK-1 and MKN-1 tumors. The stromal reaction at the tumor
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nilotinib in comparison to that in control mice (Figure 2, A and B).
A decrease in the lymphatic vessel area (Lyve-1–positive area) was also
noted, especially in the TMK-1 tumors of mice treated with both
imatinib and nilotinib (Figure 2, A and C ).
Combining Treatment of Human Gastric Cancer Growing
in the Gastric Wall of Nude Mice
We next determined whether nilotinib and everolimus, administered
in combination, have a synergistic effect. The growth and metastasis of
TMK-1 human gastric cancer cells implanted in the gastric wall of nude
mice were evaluated. The tumor incidence was 100% in all treatment
groups. Toxicity of the various treatment regimens was assessed on the
basis of change in body weight. Oral administration of nilotinib, ever-
olimus, and of the two drugs in combination did not significantly affect
bodyweight (Table 1). Tumor growth andmetastasis were not inhibited
in mice treated with nilotinib alone (vs control mice); however, tumor
growth was significantly inhibited in mice treated with everolimus
alone. Furthermore, tumor growth was much more inhibited with
the combination treatment. In five of six mice, tumors were not de-
tected macroscopically. Lymph node metastasis was significantly
inhibited only in mice treated with nilotinib and everolimus in com-
bination (Table 1).
Histopathologic Analysis of TMK-1 Tumors
To assess whether nilotinib and everolimus inhibit targeted mole-
cules, tumor sections were analyzed immunohistochemically for the
expression of p–PDGF-Rβ and p-S6RP. The phosphorylation of
PDGF-Rβ was significantly inhibited in orthotopic tumors of mice
treated with nilotinib alone or with nilotinib and everolimus in com-
bination (Figure 3A). The phosphorylation of S6 ribosomal protein was
significantly inhibited in orthotopic tumors of mice treated with ever-
olimus alone or nilotinib and everolimus in combination (Figure 3A).
The periphery of TMK-1 gastric tumors was adjacent to abundant
stroma, into which tumor cells infiltrated. In contrast, gastric tumors
in mice treated with nilotinib alone or with nilotinib and everolimus
in combination were surrounded by scanty stroma (Figure 3B and
Table 2). In addition, treatment with everolimus alone or with
nilotinib and everolimus in combination significantly reduced the
areas of vascular microvessels (Table 2), although treatment with
nilotinib alone or with nilotinib and everolimus in combination sig-nificantly reduced the number of lymphatic vessels (Figure 3B and
Table 2). The number of pericytes covering endothelial cells was also
decreased (Figure 3C and Table 2).
Proliferation of tumor cells was evaluated by staining for Ki-67. The
control group Ki-67 LI (39.6 ± 5.2) was significantly decreased with
treatment by combination treatment (13.1 ± 2.3; P < .01; Table 2).
According to TUNEL assay, the median number of apoptotic tumor
cells in control mice was 6.94 ± 1.26. The number of apoptotic cells in
tumors of mice from each of the groups treated with everolimus
was significantly increased in comparison to the number in control
mice (Table 2).
mTOR Inhibitor Reduced Expression of VEGF-A
Treatment with everolimus or nilotinib and everolimus in combina-
tion inhibited the number and area of vascular microvessels. Therefore,
we examined expression of angiogenic factor VEGF-A. Immunoreac-
tivity of VEGF-A in tumor cells was markedly suppressed by treatment
with everolimus (Figure 3B).
Discussion
In the present study, treatment with imatinib or nilotinib (PDGF-R
tyrosine kinase inhibitor) significantly reduced the stromal reaction,
area of lymphatic vessels, and pericyte coverage, consistent with our
previously reported findings [11,12]. However, tumor growth and
microvessel density were not inhibited. In contrast, treatment with
everolimus (mTOR inhibitor) induced apoptosis of tumor cells and
inhibited angiogenesis but did not influence the stromal reaction.
More interestingly, nilotinib and everolimus administered in com-
bination dramatically inhibited tumor growth, angiogenesis, stromal
reaction, and lymph node metastasis. Primary tumors were not
detected in five of six mice, and no lymph node metastasis was found
in any of the mice in the combination drug group.
Imatinib and nilotinib are well-known multiple tyrosine kinase in-
hibitors that inhibit mainly BCR-ABL, c-KIT, DDR1, DDR2, and
PDGF-Rs. BCR-ABL and c-KIT are not expressed in gastric cancer
cells (data not shown). DDRs have been reported to be activated by
different types of collagen and participate in several processes such
as cell adhesion, migration, and proliferation [34]. So far, there is no
report concerning the role of DDRs in human gastric cancer. We
reported previously that PDGF ligands are expressed by gastric cancer
cells, whereas PDGF-Rs are expressed mainly by stromal cells [12].Table 2. Immunohistochemical Analysis of TMK-1 Human Gastric Carcinoma Cells per Treatment Group.Group Tumor Cells Vascular Endothelial Cells Lymphatic Endothelial CellsKi-67 LI* (%) TUNEL† (%) MVC‡ (Per Field) MVA§ (/× 103 μm2) Pericyte Coverage¶ (%) LVA# (/× 103 μm2)Control 39.64 ± 5.24 6.94 ± 1.26 11.2 ± 1.48 6.90 ± 0.84 61.8 ± 9.89 81.50 ± 16.51
Nilotinib (100 mg/kg) 35.87 ± 1.75 6.82 ± 0.68 10.9 ± 0.82 4.34 ± 0.70** 31.8 ± 3.87** 7.21 ± 0.89††Everolimus (2 mg/kg) 31.30 ± 4.54 13.8 ± 1.07†† 6.5 ± 0.50** 1.66 ± 0.29†† 57.8 ± 7.83 51.63 ± 10.23
Nilotinib (100 mg/kg) + everolimus (2 mg/kg) 13.15 ± 2.30†† 11.0 ± 1.57** 7.2 ± 0.38 1.26 ± 0.14†† 16.2 ± 4.98** 0.84 ± 0.37††Ki-67 LI, Ki-67 labeling index; MVC, microvessel count; MVA, microvessel area; LVA, lymphatic vessel area.
Control mice were given water daily by oral gavage. Control group (n = 5), nilotinib group (n = 5), everolimus group (n = 6), and nilotinib and everlimus group (n = 6).
*Number (mean ± SE) of Ki-67–positive tumor cells per field determined by measuring 10 random 0.14-mm2 fields at ×200 magnification.
†Percentage of TUNEL-positive tumor cells (out of total number of cells) per 0.14-mm2 fields at ×200 magnification.
‡MVC was determined by counting 10 random fields at ×200 magnification.
§MVA was determined by measuring 10 random fields at ×200 magnification.
¶CD31-positive cells in direct contact with desmin-positive cells were counted in five random fields at ×200 magnification.
#LVA was determined by measuring 10 random fields at ×100 magnification.
**P < .05 versus control group values.
††P < .01 versus control group values.
1398 Molecular Targeted Therapy to Inhibit Stroma Onoyama et al. Neoplasia Vol. 15, No. 12, 2013Therefore, blockade of PDGF-R signaling by imatinib or nilotinib
may decrease the stromal reaction, areas of lymphatic vessels, and num-
ber of pericytes. Inhibition of PDGF-Rβ phosphorylation in stromal
cells was confirmed by immunofluorescence in the present study.
Everolimus is a rapalog, one of the mTOR inhibitors. The best
characterized cellular effect of rapamycin on tumor cells is the growth
retardation by cell cycle arrest in G1 phase of the cell cycle [35]. Treat-
ment with rapamycin at high concentrations results in an accumula-
tion of cells in S phase and induction of apoptosis in certain cell systems
[36]. Rapamycin is reported to reduce the production of VEGF by
tumor cells and block VEGF-mediated stimulation of endothelial cells
and tube formation [37]. Therefore, rapamycin administration can
induce apoptosis of VEGF-stimulated endothelial cells, potentially
leading to tumor vessel thrombosis [38]. These effects of rapamycin
match our findings that treatment with everolimus induced apoptosis
and inhibited VEGF expression of tumor cells.
The effects of rapamycin on lymphangiogenesis and lymph node
metastasis were recently investigated in a nude mice model, and rapa-
mycin significantly reduced the number and area of lymphatic vessels
in the primary tumor [39,40]. Lymph node metastasis was significantly
suppressed in the rapamycin-treated nude mice. The VEGF-C/vascular
endothelial growth factor receptor-3 (VEGFR-3) signal transduction
pathway plays a causal role in tumor-associated lymphangiogenesis
and lymphatic metastasis [41]. Rapamycin repressed protein and
mRNA expressions of VEGF-A and VEGF-C in B13LM cells under
both serum-starved and normal culture conditions [40], suggesting
that rapamycin inhibits lymphangiogenesis in vivo probably by inhibi-
tion of VEGF-C expression. Rapamycin also impairs downstream
signaling of VEGF-A and VEGF-C through the mTOR/S6K1 path-
way in lymphatic endothelial cells [39]. In our mouse model, inhibition
of lymphangiogenesis was observed under treatment with nilotinib but
not everolimus. Further studies are needed to determine whether
everolimus inhibits lymphangiogenesis.
Rapalogs in combination with other anticancer agents, including
standard chemotherapy agents, receptor tyrosine kinase–targeted agents,
and angiogenesis inhibitors, have shown greater activity than single-
agent rapalog, suggesting that rapalogs may be best used in combination
therapies [42]. However, the mechanisms of increased efficacy have not
been elucidated. The present study showed that PDGF-R inhibitor and
rapalog inhibited activated stromal components and neoplastic cells,
respectively. Combination therapy based on these drugs may block
cancer-stromal interaction, and mTOR inhibitor appears promising
as a therapeutic agent against stromal compartment–rich tumors.Acknowledgments
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